Jianghua Zhong

Jianghua Zhong


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2024 in Current Atherosclerosis Reports
Verified
Journal Article
Open access
PDF file
TQTing Qin
Ting Qin
TMTian-Yi Ma
Tian-Yi Ma
KHKang Huang
Kang Huang
SLShi-Juan Lu
Shi-Juan Lu
JZJianghua Zhong
Jianghua Zhong
Jian-Jun LiJian-Jun Li
Jian-Jun Li
: Purpose of Review: The primary objective of this review is to explore the pathophysiological roles and clinical implications of lipoprotein(a) [Lp(a)] in the context of atherosclerotic cardiovascular disease (ASCVD). We seek to understand how Lp(a) contributes to inflammation and arteriosclerosis, aiming to provide new insights into the mechanisms of ASCVD progression. Recent Findings: Recent research highlights Lp(a) as an independent risk factor for ASCVD. Studies show that Lp(a) not only promotes the inflammatory processes but also interacts with various cellular components, leading to endothelial dysfunction and smooth muscle cell proliferation. The dual role of Lp(a) in both instigating and, under certain conditions, mitigating inflammation is particularly noteworthy. Summary: This review finds that Lp(a) plays a complex role in the development of ASCVD through its involvement in inflammatory pathways. The interplay between Lp(a) levels and inflammatory responses highlights its potential as a target for therapeutic intervention. These insights could pave the way for novel approaches in managing and preventing ASCVD, urging further investigation into Lp(a) as a therapeutic target.

5 January 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
GWGan Wang
Gan Wang
TMTian-Yi Ma
Tian-Yi Ma
KHKang Huang
Kang Huang
JZJianghua Zhong
Jianghua Zhong
SLShi-Juan Lu
Shi-Juan Lu
Jian-Jun LiJian-Jun Li
Jian-Jun Li
Diabetic cardiomyopathy (DCM), one of the common complications of diabetes, presents as a specific cardiomyopathy with anomalies in the structure and function of the heart. With the increasing prevalence of diabetes, DCM has a high morbidity and mortality worldwide. Recent studies have found that pyroptosis, as a programmed cell death accompanied by an inflammatory response, exacerbates the growth and genesis of DCM. These studies provide a theoretical basis for exploring the potential treatment of DCM. Therefore, this review aims to summarise the possible mechanisms by which pyroptosis promotes the development of DCM as well as the relevant studies targeting pyroptosis for the possible treatment of DCM, focusing on the molecular mechanisms of NLRP3 inflammasome-mediated pyroptosis, different cellular pyroptosis pathways associated with DCM, the effects of pyroptosis occurring in different cells on DCM, and the relevant drugs targeting NLRP3 inflammasome/pyroptosis for the treatment of DCM. This review might provide a fresh perspective and foundation for the development of therapeutic agents for DCM.

1 September 2024 in Panminerva Medica
Verified
Journal Article
Closed access
STShilin Tang
Shilin Tang
YWYang Wang
Yang Wang
TMTanya Ma
Tanya Ma
SLShijuan Lu
Shijuan Lu
KHKang Huang
Kang Huang
JZJianghua Zhong
Jianghua Zhong
Article: MiR-30d inhibits cardiomyocytes autophagy promoting ferroptosis after myocardial infarction - Panminerva Medica 2020 Jul 27 - Minerva Medica - Journals

14 February 2024 in International Wound Journal
Verified
Journal Article
Open access
TMTian Yi Ma
Tian Yi Ma
STShi Lin Tang
Shi Lin Tang
BWBin Wang
Bin Wang
GWGan Wang
Gan Wang
CSChang Ming Sun
Chang Ming Sun
JZJianghua Zhong
Jianghua Zhong
Ischemic ulcers pose a multifaceted clinical dilemma for patients with atherosclerosis, frequently compounded by suboptimal wound healing mechanisms. The dual function of Transforming Growth Factor Beta 3 (TGF‐β3) in ischemic ulcer healing is not fully comprehended, despite its involvement in modulating inflammatory responses and tissue regeneration. The main aim of this investigation was to clarify the functions and mechanisms by which TGF‐β3 regulates inflammatory responses and promotes wound healing in patients with ischemic ulcers who have atherosclerosis. Between August 2022 and November 2023, this cross‐sectional investigation was conducted on 428 patients diagnosed with atherosclerotic ischemic ulcers in Haikou, China. The expression and function of TGF‐β3 were examined throughout the different stages of wound healing, including inflammation, proliferation and remodelling. In addition to documenting patient demographics and ulcer characteristics, an analysis was conducted on biopsy samples to determine the expression of TGF‐β3, pro‐inflammatory and anti‐inflammatory markers. A subset of patients were administered topical TGF‐β3 in order to evaluate its therapeutic effects. The expression pattern of TGF‐β3 was found to be stage‐dependent and significant, exhibiting increased levels during the phase of inflammation and reduced activity in subsequent phases. TGF‐β3 levels were found to be greater in ulcers that were larger and deeper, especially in inflammatory phase. TGF‐β3 applied topically induced discernible enhancement in ulcer healing parameters, such as reduction in ulcer depth and size. The therapeutic significance of TGF‐β3 was emphasised due to its twofold function of regulating the inflammatory environment and facilitating the regeneration of damaged tissues. Ischemic ulcer lesion healing is significantly influenced by TGF‐β3, which functions as an anti‐inflammatory and pro‐inflammatory mediator. Its correlation with ulcer characteristics and stages of healing suggests that it may have utility as a targeted therapeutic agent.

25 March 2021 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
TMTianyi Ma
Tianyi Ma
Yuli HuangYuli Huang
Yuli Huang
WLWensheng Li
Wensheng Li
JZJianghua Zhong
Jianghua Zhong
HYHui Yang
Hui Yang
YHYunzhao Hu
Yunzhao Hu
Background. At present, COVID-19 is sweeping the world, and all countries are actively responding. During the COVID-19 epidemic, the treatment of patients with acute myocardial infarction (AMI) may be affected. Methods. We reviewed data of patients with AMI from January 23 to April 23, 2020 (2020), and January 23 to April 23, 2019 (2019), who were admitted to two hospitals from Southern China. We collected clinical characteristics, comorbidities, treatment, prognosis, and key time segments to analyze. Results. The total number of patients that had been diagnosed with AMI in the two hospitals was 218 in 2020 and 260 in 2019. The number of AMI patients that were admitted to hospitals per day decreased in 2020. The percentage of patients with AMI who refused hospitalization in 2020 was significantly higher than that in 2019 (5.0% vs 1.5%, ). There is no statistical difference in symptoms of the first medical contact (S2FMC) time between 2020 and 2019 ( ). Door-to-balloon (D2B) time of ST-elevation myocardial infarction (STEMI) patients who were treated with a primary percutaneous coronary intervention (pPCI) in 2020 was 79 (63.75–105.25) mins, while D2B time in 2019 was 57.5 (41.5–76.5) mins, which was statistically different from the two groups. Conclusions. COVID-19 had an impact on the number of AMI patients who were admitted to hospitals and the time of treatment. During the COVID-19 epidemic, the number of AMI patients that were admitted to hospitals per day was decreased, while the percentage of AMI patients that refused therapy in these two hospitals increased, and the D2B time of STEMI patients was also delayed.

1 August 2007 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
JZJianghua Zhong
Jianghua Zhong
XCXiao-Pan Chen
Xiao-Pan Chen
MYMei-Ling Yun
Mei-Ling Yun
WLWei-Jing Li
Wei-Jing Li
YCYan-Fang Chen
Yan-Fang Chen
ZYZhen Yao
Zhen Yao
APS (Acta Pharmacologica Sinica), the top pharmacology research journal based in China, publishes original articles and reviews on all aspects of pharmacology and the related life sciences